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HERPES SIMPLEX VIRUS TYPE 2 ANTIBODIES: 
HIGH PREVALENCE IN MONOGAMOUS 
WOMEN IN COSTA RICA 
MARK W. OBERLE. LUIS ROSERO-BlXBY. FRANCIS K. LEE. 
MARIA SANCHEZ-BRAVERMAN, ANDREJ. NAHMIAS, AND 
MARY E. GUINAN 
U.S. Depanment of Health and Human Services. Centers for Disease Control. Atlanta, Geor!?ia," 
Unn·ersit_v of Costa Rica. San Jose, Cosw Rica; and 
Emory Universit}'. Atlama. Georgia 
Abstract. We studied the prevalence of antibody to Herpes simplex virus types I and 
2 (HSV-I and HSV-2) in 766 randomly selected Costa Rican women 25-59 years of age 
in a national household survey in 1984-1985. Overall, 97.1% were seropositive for HSV-l 
and 39.4% for HSV -2. Only L I% of HSV -2 seropositive women gave a history of symp-
tomatic genital herpes. HSV-2 virus antibody increased with age and with the number of 
lifetime sexual partners. HSV -2 seroprevalence among women who reported only I lifetime 
sexual partner was almost twice as high as the preYalence among women who denied sexual 
experience (30.5% vs. 17.7%) and reached 79.2% among women with <:::4 partners. HSV-2 
seroprevalence was lower among women whose partners used condoms: 28.9% for those 
who had used condoms for at least 2 years vs. 44.3% for those who never used condoms. 
Few population-based studies have examined 
the descriptive epidemiology and seroprevalence 
of herpes simplex virus (HSV) infection. Some 
of the obstacles to gathering such information 
are the difficulty in obtaining population-based 
serum samples, the lack of medical and sexual 
history data of patient populations in which sero-
prevalence studies have been done, and the lack 
of a highly specific serologic test to differentiate 
between antibody to type I and type 2 HSV. 
The recent development of type-specific se-
rologic techniques has made possible more pre-
cise estimates of the extent of infection with 
herpes simplex type 2 (HSV-2).' Between 1978 
and 1980, the prevalence of antibody to HSV-2 
in the white residential population of Toronto, 
Canada, was estimated as 15.5% by a precise 
method for distinguishing between HSV -1 and 
HSV-2.2 Using another new, more specific se-
rologic method, preiiminary data from a U.S. 
national survey showed a prevalence of HSV -2 
antibody of 16.4% amttng non-institutionalized 
civilian residents. 3 
We report the first nationally representative 
data from Costa Rica on the prevalence of an-
tibody to types 1 and 2 herpes simplex virus 
(using the same specific serolog.ic test used in the 
U.S. national survey) and the first population-
based study that examines demographic char-
acteristics and medical and sexual histories in 
relation to the presence of HSV -2 antibody. 
MA TERlALS AND METHODS 
Compared with women in developed nations, 
Costa Rican women have a higher incidence of 
cervical cancer and a lower incidence of.breast 
cancer.0 In 1984-1985, the Costa Rican De-
mographic Association in collaboration with the 
Centers for Disease Control (CDC), the Costa 
Rican Social Security Administration. the Min-
istry ofHealth, and Family Health International 
conducted a case-control study of these 2 can-
cers. Details of the study design and population 
have been reported elsewhere.6-10 
The current analysis is restricted to the pop-
ulation-based control series from that study and 
describes seroprevalence ofHS V antibody rather 
than incidence. The control sample consisted of 
a cross-section of women in the 25-59 year age 
group. They were selected in a nationally rep-
resentative cluster sample survey based on the 
June 1984 census. Sample points in sparsely set-
tled areas. representing 5% of the population, 
were excluded. Of the 938 women eligible as 
controls, 92.8% were interviewed in their homes 
by trained female interviewers using a standard 
questionnaire modified from the CDC Cancer 
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and Steroid Hormone Study. 11 Interviews lasted 
an averageof40 min and focused on the women's 
reproductive. medical. and sexual histories. 
After receiving informed consent. laboratory 
technicians obtained serum specimens from 88% 
of the interviewed control women. Sera were 
analyzed for ami bodies to HSV -1 and HSV -2 (at 
the Division of Pediatric Infectious Diseases, 
Emory University) with a type-specific glycopro-
tein antigen, 1 and for antibody to Chlamydia 
trachomatis'~ (at the Chlamydia Laboratory, San 
Francisco General Hospital). The MHA-TP and 
RPR tests for syphilis were performed at the STD 
Laboratory, Center for Infectious Diseases, CDC. 
Because the social and demographic charac-
teristics of women who had a serum specimen 
drawn did not differ from those of women who 
did not, 13 the analysis was restricted to those 
women for whom a serum specimen was ob-
tained. Sampling fractions used in selecting con-
trols varied by age group in order to match the 
age distribution of the cancer cases for the orig-
inal case control study. In order tb obtain pop-
ulation estimates of seroprevalence, the results 
for the current analysis were age-weighted by the 
inverse of the sampling fractions to compensate 
for the over-sampling of women in certain age 
groups. 14 Demographic and reproductive history 
variables were cross-tabulated with age and with 
the number of lifetime sexual partners to char-
acterize seropositivity. Cells with <25 women 
are not presented. Since the population survey 
was based on a multi-stage, duster sample meth-
odology, confidence intervals were calculated us-
ing a Taylor series approximation of the vari-
ance.14 
RE.StiLTS 
Fewer than I o/o of the women reported a his-
tory of oral herpes lesions. The prevalence of 
HSV-1 antibody was 97.1% with minimal dif-
ferences by population subgroups. When ana-
lyzed by age, region, or education level, >90% 
of the women in each subgroup were seropositive 
for HSV-1. 
Very few women reported a history of sexually 
transmitted diseases. Antibody to HSV-2 was 
detected in 39 .4%, but only 1.1% of seropositive 
women reported a history of genital herpes le-
sions. More than half the women had antibody 
to Chlamydia trachoma tis (56.1 %) and 6.4% had 
a reactive syphilis 1!\lHA-TP) serology. Women 
who had serologic evidence of past syphilis in-
fection were almost twice as likely to !lave an-
tibody to HSV -2 ns women nonreaCiive for syph-
ilis r77.5% vs. 36.8%). Simiiariy, women with 
serological evidence of past chlamydia} infection 
were almost twice as likely to be seropositive for 
HSV -2 as women with no evidence of chlamyd:.. 
ial infections (50.3% vs. 25.9%). Of 44 women 
who had serological evidence of both syphilis 
and chlamydia! intection, 85.1% were seroposi-
tive for HSV-2; only 26.7n1J ofthe 313 women 
who were seronegative for both syphilis and chla-
mydia had serological evidence ofHSV-2 infec-
tion. 
When analyzed by geographic region. the prev-
alence of HSV-2 antibody was highest (48.7%) 
in urban areas outside the central valley. chiefly 
the port cities of Limon and Puntarenas (data 
not shown). Education was inversely related to 
. seroprevalence ofHSV-2, even when controlled 
for age or for the number of lifetime sexual part-
ners (Table 1). Previously married women had 
a seroprevalence almost twice as high as that of 
currently married women (62.3% vs. 35.2%). 
The number of lifetime sexual partners was a 
strong predictor of seropositivity for HSV -2 for 
both older and younger women (Table 2). Sero-
prevalence among women who reported only I 
sexual partner in their life was almost twice as 
high as the prevalence for the 36 women who 
denied having coitus (30.5% vs. 17. 7%}. Sera-
prevalence again doubled for women with 2 sex-
ual partners compared to I partner (57.7% vs. 
30.5%). Similarly, 61.6%ofwomen with 3 sexual 
partners during their life and 79.2% of women 
with 2:.4 partners were seropositive. 
Seropositivity increased with age, even when 
controlled for the number otlifetime sexual part-
ners (Table 1). However, in each age group, the 
prevalence of HSV -2 antibody among women 
with 2:.2 lifetime sexual partners was approxi-
mately twice as high as that of women with I or 
no partners. 
Although women who reported a young age at 
first coitus had a higher seroprevalence, this dif-
ference diminished when controlled for the num-
ber of lifetime sexual partners (Table 2). Sero-
positivity increased with the number of 
pregnancies, but this relationship wa.s pro-
nounced only for women with ~2lifetime sexual 
partners. HSV-2 seroprevalence was not related 
to use of specific contraceptives, except for con-
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TABLE I 
Perceruage o/ women wuh HSV-2 amibod.r by selected demographic characterisucs 
Total 25-39 40-59 0-J 2:2 
., No. women ... No. women ., :t-1o. women % No. wom~n ,. No. 'WOtncn 
Age (years) 
25-29 32.8 (122)t 25.6 (86) 50.0 (36) 
30-39 38.5 (270) 26.7 (187) 65.9 (82) 
40-49 44.6 (194) 32.6 (126) 66.0 (67) 
50-59 46.1 (180) 37.7 (138) 73.8 (42) 
Education 
None 54.9 (79) -t 555 (56) 34.8 (43) 77.2 (36) 
Primary incomplete 46.1 (258) 50.8 (89) • 42.5 (169) 32.9 (173) 71.5 (84) 
Primary complete 37.9 (187) 34.1 (113) 46.8 (74) 29.8 (129) 57.0 (57) 
Secondary 33.1 (172) 28.9 (123) 50.3 (49) 26.7 (132) 52.4 {40) 
University 26.7 (70) 25.8 (44) 28.9 (26) 25.0 (60) -t 
Marital Status 
In union 35.2 (542) 33.1 (299) 39.3 (243) 28.1 (423) 59.4 (117) 
Sepiwidldiv 62.3 (106) 65.9 (28) 60.3 (78) 50.8 (54) 73.9 (52) 
Single 41.2 (118) 36.4 (65) 50.3 (53) 24.0 (60) 60.0 (58) 
Total 39.4 (766) 35.9 (392) 45.3 (374) 29.6 (537) 62.5 (227) 
• Two •omen with unbmvn numbo"s of sexual partners excluded. 
t Nll!Dbers in parenlh<sc:s refer to 1.he unweighted number of M)m<:n in each celL 
t Less - 25 <:ascS. 
doms. Women whose partners had used con- than women whose partners had used condoms 
doms were less likely to have antibody to HSV -2 for <2 years. An apparent protective effect of 
than those whose partners had never used con- condom use also occurred when stratified by age 
doms (rable 3). Women whose partners had used or by the number oflifetime sexual partners (Ta-
condoms for ::::2 years had a lower prevalence ble 4). 
TABLE 2 
Percem.age ofwomen with HSV-2 antibody by age at .first intercourse, number of sa7Uli panners, and numbe.r 
of pregnancies • · 
Age lvearsl No. sexual partners• 
Toral 25-39 40-59 0-J ;;,2 
,. No. women % No. women % No. women <;. No. women % No. women 
No. sexual partners 
0 17.7 (36)t -t -:j: 
1 30.5 (501) 27.6 (251) 35.1 (250) 
2 57.7 (133) 54.4 (65) 62.7 (68) 
2:3 68.8 (94) 64.0 (53) 78.0 (41) 
Age at lust intercourse§ 
None 17.7 (36) -:j: -:j: 17.7 (361 NA 
16 49.3 (112) 44.9 {66) 59.5 (46) 33.8 (49) 60.8 (63) 
1~19 42.2 (280) 41.4 (134) 43.3 (!46\ 28.5 (178) 65.7 (102> 
;::20 35.8 (336) 30.9 (169) 43.6 (167) 30.9 (273) 51.U {61) 
Number of pregnancies 
0 25.1 (70). 19.1 (42) 41.6 (28) 23.1 (60) -:!: 
1-2 32.6 (161) 27.6 ( 117) 55.1 (44) 26.7 (120) 51.4 (41) 
3-4 43.9 (222) 41.8 (152) 50.2 (70) 33.9 (1501 63.1 (71) 
;:;s 44.8 (313) 50.2 (81) 42.1 (232) 30.6 (207) 70.4 (106) 
Total 39.4 1766) 35.9 (392) 45.3 (374) 29.6 (537) 62.5 (227) 
u."'men 
t Numb<:n in 1n each ceJL 
; l..css limn cases.. 
§Two women '\\-lth unknuwn age at first interrourr-e. 
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TABLE 3 
Percentage ~~!women wirh HSV-! amiboa:v bl' condom liSe and age group 
25-39 
--10-59 
Tmal 
40.6 = 6.3 
48.9 6.:! 
44.3 - 4.9 
?ercem = L-16 SE* 
33.0 ± 8.8 24.6 ll.2 
36.1 = 1::'..0 
28.9 ± 8.7 
35.9::: 5.0 
35.6 12.8 ..l5.3- 5.3 
33.5 :t 7.8 39.-1 = 3.8 
"'CT = '.15%.. 
DISCUSSION 
The high prevalence of specific HSV-2 anti-
body in Costa Rican women is consistent with 
the limited previous studies from Central Amer-
ica. One previous Costa Rican study reported 
that I 0 of20 selected clients in a family planning 
clinic had neutralizing antibody to HSV-2. 15 In 
Guatemala City, Guatemala. 45 of 60 selected 
outpatients were seropositive for HSV -2 as de-
termined by an ELISA test (Juan Manual and 
Amaya Ferman, University of San Carlos, Gua-
terqala City, Guatemala, personal communica-
tion). A more specific serological text was used 
in Herrera Province, Panama. There, 33% of 
control subjects in a cervical cancer case~control 
study had HSV -2 antibody.' 6 None of these Pan-
amanian women reported a history of genital 
herpes. 
The seroprevalence of HSV-2 increased with 
age and varied by marital status and educational 
leveL However, the number of lifetime sexual 
partners demonstrated the most dramatic gra-
dient for seropositivity. Two-fold differences in 
seroprevalence were observed between women 
with I sexual partner and women with no sexual 
experience and for women with 2 partners as 
compared to women with I sexual partner. 
Women with <::4lifetime sexual partners had a 
seropositivity of 79.2%, compared with 17.7% 
among women with no history of coitus. This 
latter group included only 6 seropositive wome~ 
and may have reflected perinatal infection, in-
accurate sexual histories, oral transmission of 
HSV -2, or residual cross-reactivity with HSV -I. 
Since most women in chis study (65.4%) re-
ported only I sexual partner in their !ifr:, the 
seroprevalence estimate for the total population 
is primarily determined by the prevalence in this 
subgroup. Yet the seroprevalence among these 
monogamous women was high (30.5%). This 
strongly suggests that risk factors related to male 
sexual behavior, which were not measured in this 
study, are responsible for the high seroprevalence 
ofHSV-2 in Costa Rican women. 
Very few women reported a history of genital 
herpes or any other sexually transmitted disease 
(STD). Some Costa Rican women may have been 
hesitant to report symptomatic genital herpes in-
fection, or may not have been informed of the 
diagnosis by a clinician. But most genital herpes 
infections in Costa Rica are probably asympto-
matic, as in other countries. 16• 17 Women with 
serological evidence for syphilis or chlamydia! 
infection were twice as likely to have HSV -2 an-
tibody than women with no serologic evidence 
for these diseases. These results suggest that 
women who had l STD were likely to have > 1. 
Condom use has been associated with a de-
creased risk for several sexually transmitted dis-
eases. ' 8 In this study, the pattern of condom use 
(Tables 3, 4) is consistent with a protective effect 
against HSV-2. Women whose partners used 
condoms had a lower prevalence of HSV -2 an-
tibody in both age groups as compared to non-
users. Among younger women and women with 
only I sexual partner, the long-term use of con-
doms(<:: 2 years) had a slightly lower HSV -2 ser-
oprevalence than short-term users. However, 
since this is a prevalence rather than an incidence 
TABLE 4 
Percentage of women wirh HSV· 2 antibody by condom use and number of sexual panners 
No. partners Never used condoms Used condoms 1-23 months Used condoms ,.24 months Tolal 
Percent :t 1.96 SE* 
34.6 ± 5.8 27.7 :t 8.4 21.2 ± 8.4 30.5 ± 4.1 
2:2 68.5 ± 7.4 49.8 ± 16.0 52.9 21.4 62.5 ± 7.1 
Total 44.3 ± 4.9 33.5 ± 7.8 28.9 ± 8.7 39.4 ± 3.8 
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study, condom use could have occurred before 
or after HSV -2 infection. 
The cross-sectional study design JL?O and the 
restriction to women 25-59 years of age impedes 
our ability to identify risk factors for HSV -2 in-
fection. 
The view& of the author& do not purport to reflect the 
positions ofUSAID. 
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